Treatment and Survival of Small-bowel Adenocarcinoma in the United States

Young, Jenny; Mongoue-Tchokote, Solange; Wieghard, Nicole; Mori, Motomi; Vaccaro, Gina M.; Sheppard, Brett C.; Tsikitis, V. Liana

doi:10.1097/dcr.0000000000000562

Cited by 74 publications

(84 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With none of the risk factors (as in the present case), a jejunal adenocarcinoma is an even rarer diagnosis. Recently, Young et al [8] have revealed that surgery seems to be the only treatment that improves survival on small bowel adenocarcinoma, and no benefit was seen by adding chemotherapy regimens. Even so, the 5-year survival rate after diagnosis is around 30% [5] .…”

Section: Discussionmentioning

confidence: 99%

Intestinal Obstruction of Uncommon Cause and Point-of-Care Ultrasonography - Where Do We Stand

Capela

Sousa

Caldeira³

et al. 2017

GE Port J Gastroenterol

View full text Add to dashboard Cite

Malignant neoplasms of the small bowel, especially from the jejunum, are among the rarest types of cancer. Given its location, a delayed diagnosis is frequent and sometimes only made in an emergency context. The authors present a case of intestinal obstruction, where ultrasonography was pivotal in establishing a diagnosis. Point-of-care ultrasonography seems to be particularly sensitive in assessing emergency patients with abdominal pain, allowing effective orientation and saving human and technical resources.

show abstract

Section: Discussionmentioning

confidence: 99%

Intestinal Obstruction of Uncommon Cause and Point-of-Care Ultrasonography - Where Do We Stand

Capela

Sousa

Caldeira³

et al. 2017

GE Port J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The rarity of small-intestine adenocarcinoma restricts studies of its treatment and prognosis. Moreover, because the small intestine is located near the large intestine, small-intestine adenocarcinoma is generally considered to be similar to colorectal adenocarcinoma, and some of the applied treatments are therefore based on colorectal cancer [6]. There has been far less research into the prognosis of smallintestine adenocarcinoma compared to colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma

Wang

Yang

Lyu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The objective of this study was to develop a practical nomogram for predicting the cancer-specific survival (CSS) of patients with small-intestine adenocarcinoma. Methods: Patients diagnosed with small-intestine adenocarcinoma. between 2010 and 2015 were selected for inclusion in this study from the Surveillance, Epidemiology, and End Results (SEER) database. The selected patients were randomly divided intothe training and validation cohorts at a ratio of 7:3.The predictors of CSS were identified by applying both forward and backward stepwise selection methods in a Cox regression model. The performance of the nomogram was measured by the concordance index (C-index), the area under receiver operating characteristic curve (AUC), calibration plots, the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), and decision-curve analysis (DCA). Results: Multivariate Cox regression indicated that factors including age at diagnosis, sex, marital status, insurance status, histology grade, SEER stage, surgery status, T stage, and N stage were independent covariates associated with CSS. These factors were used to construct a predictive model, which was built and virtualized by a nomogram. The C-index of the constructed nomogram was 0.858. The AUC values indicated that the established nomogram displayed better discrimination performance than did the seventh edition of the American Joint Committee on Cancer TNM staging system in predicting CSS. The IDI and NRI also showed that the nomogram exhibited superior performance in both the training and validation cohorts. Furthermore, the calibrated nomogram predicted survival rates that closely corresponded to actual survival rates, while the DCA demonstrated the considerable clinical usefulness of the nomogram. Conclusion: We have constructed a nomogram for predicting the CSS of small-intestine adenocarcinoma patients. This prognostic model may improve the ability of clinicians to predict survival in individual patients and provide them with treatment recommendations.

show abstract

“…The mortality rate of patients with colon cancer has decreased owing to improved detection, but the incidence of colon cancer continues to increase 2. Considerable progress in the development of chemotherapy for advanced colon cancer has been observed in the recent decade 3. The epidermal growth factor receptor (EGFR) has been reported as a critical therapeutic target for the treatment of colon cancer 4.…”

Section: Introductionmentioning

confidence: 99%

Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Shi¹,

Zheng²,

et al. 2017

OTT

View full text Add to dashboard Cite

Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer.

show abstract

Treatment and Survival of Small-bowel Adenocarcinoma in the United States

Cited by 74 publications

References 21 publications

Intestinal Obstruction of Uncommon Cause and Point-of-Care Ultrasonography - Where Do We Stand

Intestinal Obstruction of Uncommon Cause and Point-of-Care Ultrasonography - Where Do We Stand

A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma

Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Contact Info

Product

Resources

About